Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463244 | 1.00 | NOD2 (0.49) | NOD2NOD1MAPTCCR2ELANE | |
| SCHEMBL4196083 | 0.87 | NOD2 (0.54) | NOD2NOD1MAPTCCR2ELANE | |
| SCHEMBL16732758 | 0.85 | MAPT (0.54) | NOD2NOD1MAPTCCR2ELANE | |
| SCHEMBL5889460 | 0.85 | MAPT (0.53) | NOD2NOD1MAPTCCR2ELANE | |
| SCHEMBL29463270 | 0.84 | NOD2 (0.49) | NOD2NOD1MAPTCCR2ELANE | |
| SCHEMBL23045592 | 0.84 | NOD2 (0.49) | NOD2NOD1MAPTCCR2ELANE | |
| SCHEMBL23045560 | 0.84 | NOD2 (0.51) | NOD2NOD1MAPTCCR2ELANE | |
| SCHEMBL23045588 | 0.84 | NOD2 (0.51) | NOD2NOD1MAPTCCR2ELANE | |
| SCHEMBL29463273 | 0.84 | NOD2 (0.51) | NOD2NOD1MAPTCCR2ELANE | |
| SCHEMBL29463226 | 0.84 | NOD2 (0.51) | NOD2NOD1MAPTCCR2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465588-B2 | Indole carboxamide derivative and pharmaceutical composition containing same | KUKJE PHARMA CO., LTD. (KR) | 2025-11-11 | — | — | US | disclosed |
| US-20230000821-A1 | INDOLE CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KUKJE PHARMA CO., LTD. (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-4023638-A1 | INDOLE CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kukje Pharma Co., Ltd. (KR) | 2022-07-06 | — | — | EP | disclosed |
| CN-114302874-A | Indole carboxamide derivatives and pharmaceutical compositions comprising same | 国际药品株式会社 | 2022-04-08 | — | — | CN | disclosed |
| WO-2021040393-A1 | INDOLE CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 국제약품 주식회사 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465588-B2 | Indole carboxamide derivative and pharmaceutical composition containing same | PTGES, PTGES2, PTGS1 | NOD2 1824/4885NOD1 805/4885MAPT 304/4885 |
| US-20230000821-A1 | INDOLE CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | PTGES, PTGES2, PTGS1 | NOD2 1824/4885NOD1 805/4885MAPT 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.